Tyra shares slide after bladder-cancer drug misses investor efficacy bar on September 10, 2026 complete-response rate dabogratinib FGFR3-altered Malignant neoplasm of urinary bladder Non-Muscle Invasive Bladder Neoplasms stocks SURF302 Tyra Biosciences TYRA-300 +